# Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

> **NCT06325566** · PHASE3 · RECRUITING · sponsor: **Mesoblast, Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Degenerative Disc Disease

## Interventions

- **DRUG:** Rexlemestrocel-L + HA mixture
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT06325566
- **Lead sponsor:** Mesoblast, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-03
- **Primary completion:** 2026-10
- **Final completion:** 2027-10
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06325566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06325566, "Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06325566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*